Mandate

Vinge has advised VNV Global AB (publ) in connection with a directed share issue

February 19, 2021 Capital Markets and Public M&A

Vinge has advised VNV Global AB (publ), an investment company listed on Nasdaq Stockholm, in connection with a directed share issue whereby VNV Global receives approximately SEK 1,166 million in issue proceeds.

The subscription price was determined to SEK 100 per share through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The company intends to use the expected net proceeds from the transaction to take advantage of investment opportunities in the near term, deploying capital in both existing investments in need of further growth capital and in to a pipeline of potential new investment opportunities.

VNV Global is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The common shares of VNV Global are listed on Nasdaq Stockholm, Mid Cap segment, with the ticker VNV.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg and Eléonore Friberg.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025